Abstract
Polycystic ovary syndrome (PCOS) is a common disorder affecting (depending on the population studied and the definition of the syndrome) between 5 to 20% of reproductive age women.1 If the middle of this range is considered as a realistic prevalence, then PCOS may be the most prevalent endocrine disorder in women. In spite of the widespread presence of PCOS, its precise definition still eludes both investigators and practitioners. Most consensus definitions describe PCOS as a disorder characterized by chronic anovulation and the presence of some degree of hyperandrogenism, with the exclusion of specific disorders that may lead to similar phenotypes, particularly, 21-hydroxylase deficiency and other forms of congenital adrenal hyperplasia. The definition proposed in 1990 by the National Institutes of Health Conference on PCOS requires a minimum of two criteria: menstrual abnormalities due to oligo- or anovulation, and hyperandrogenism of ovarian origin. Other disorders, such as 21-hydroxylase deficiency, androgen secreting tumors, and hyperprolactinemia, must be excluded.2
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Knochenhauer ES, Key TJ, Kahsar-Miller M, Waggoner W, Boots LR, Azziz R. Prevalence of the polycystic ovarian syndrome in unselected black and white women of the Southeastern United States: a prospective study. J Clin Endocrinol Metab 83: 3078–3082, 1998.
Zawadzki JK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A ed. Polycystic Ovary Syndrome. Boston: Blackwell Scientific, 337–384, 1995.
Speroff L, Glass RH, Kase NG, eds. Anovulation and the polycystic ovary. In: Clinical gynecologic endocrinology and infertility, 6`h ed. Baltimore: Lippincott Williams and Wilkins; 487–522, 1999.
Kovacs GT, ed. Polycystic ovary syndrome. Cambridge University Press, Cambridge, UK, 2000.
Dunaif A. Hyperandrogenic anovulation (PCOS): a unique disorder of insulin action associated with an increased risk of non-insulin-dependent diabetes mellitus. Am J Med [Suppl] 98: 33S - 39S, 1995.
Chereau, A. Mémoires pour servir a l’étude des maladies des ovaries. Paris: Fortin, Masson and Cie, 1844.
Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol 29: 181–186, 1935.
Culiner A, Shippel S. Virilism and thecal cell hyperplasia of the ovary syndrome. J Obstet Gynaecol Br Comm 56: 439–445, 1949.
McArthur JW, Ingersoll FW, Worcester J. The urinary excretion of interstitial-cell and follicle-stimulating hormone activity by women with diseases of the reproductive system. J Clin Endocrinol Metab 18: 1202 1215, 1958.
De Vane GW, Czekala NM, Judd HL, Yen SS. Circulating gonadotropins, estrogens, and androgens in polycystic ovarian disease. Am J Obstet Gynecol 121: 496–500, 1975.
Poretsky L, Cataldo N, Rosenwaks Z, Giudice L. The insulin-related ovarian regulatory system in health and disease. Endocr Rev 20: 535–582, 1999.
Zumoff B, Freeman R, Coupey S, Saenger P, Markowitz M, Kream J. A chronobiologic abnormality in luteinizing hormone secretion in teenage girls with the polycystic-ovary syndrome. N Engl J Med 309: 1206–1209, 1983.
McLachlan RI, Healy DL, Burger HG. The ovary. In: Felig P, Baxter JD, Broadus AE, Frohman LA, eds. Endocrinology and Metabolism. 2nd éd. New York: McGraw-Hill Book Company; 951–983, 1987.
Pang S, Softness B, Sweeney WJ, New MI. Hirsutism, polycystic ovarian disease, and ovarian 17-ketosteroid reductase deficiency. N Engl J Med 316: 1295–1301, 1987.
Nelson VL, Qin K-N, Rosenfeld RL, Wood JR, Penning TM, Legro RS, Srauss JF III, McAllister JM. The biochemical basis for increased testosterone production in theca cells propagated from patients with polycystic ovary syndrome. J Clin Endocrinol Metab 86: 5925–5933, 2001.
Poretsky L and Kalin M. The gonadotropic function of insulin. Endocr Rev 8: 132–141, 1987.
Archard C, Thiers J. Le virilisme pilaire et son association a l’insuffisance glycolytique (diabete des femmes a barbe). Bull Acad Nat Med 86: 51, 1921.
Kahn CR, Flier JS, Bar RS, Archer JA, Gorden R, Martin MM, Roth J. The syndromes of insulin resistance and acanthosis nigricans: insulin-receptor disorders in man. N Engl J Med 294: 739–745, 1976.
Flier JS, Kahn CR, Roth J, Bar RS. Antibodies that impair insulin receptor binding in an unusual diabetic syndrome with severe insulin resistance. Science 190: 63–65, 1975.
Taylor SI, Moller DE. Mutations of the insulin receptor gene. In: Moller DE ed. Insulin Resistance. New York: John Wiley and Sons; 83–121, 1993.
Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. Endocr Rev 18: 774–800, 1997.
Dunaif A, Book CB, Schenker E, Tang Z. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest 96: 801–810, 1995.
Poretsky L, Smith D, Seibel M, Pazianos A, Moses AC, Flier JS. Specific insulin binding sites in the human ovary. J Clin Endocrinol Metab 59: 809–811, 1984.
Poretsky L, Grigorescu F, Seibel M, Moses AC, Flier JS. Distribution and characterization of the insulin and IGF-I receptors in the normal human ovary. J Clin Endocrinol Metab 61: 728–734, 1985.
El-Roeiy A, Chen X, Roberts VJ, Shimasaki S, Ling N, LeRoith D, Roberts Jr CT, Yen SS. Expression of the genes encoding the insulin-like growth factors (IGF-I and II), the IGF and insulin receptors, and IGFbinding proteins 1–6 and the localization of their gene products in normal and polycystic ovary syndrome ovaries. J Clin Endocrinol Metab 78: 1488–1496, 1994.
Barbieri RL, Makris A, Ryan KJ. Effects of insulin on steroidogenesis in cultured porcine ovarian theca. Fertil Steril 40: 237–241, 1983.
Poretsky L, Clemons J, Bogovich K. Hyperinsulinemia and human chorionic gonadotropin synergistically promote the growth of ovarian follicular cysts in rats. Metabolism 41: 903–910, 1992.
Poretsky L, Chandrasekher YA, Bai C, Liu HC, Rosenwaks Z, Giudice L. Insulin receptor mediates inhibitory effect of insulin, but not of insulin-like growth factor (IGF)-1, on binding protein 1 (IGFBP-1) production in human granulosa cells. J Clin Endocrinol Metab 81: 493496, 1996.
Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev 12: 3–13, 1991.
Joslin EP, Root HF, White P. The growth, development and prognosis of diabetic children. JAMA 85: 420–422, 1925.
Zumoff B, Miller L, Poretsky L, Levitt C, Miller E, Heinz U, Denman H, Jandorek R, Rosenfeld R. Subnormal follicular-phase serum progesterone levels and elevated follicular-phase serum estradiol levels in young women with insulin-dependent diabetes. Steroids 55: 560–564, 1990.
Poretsky L, Bhargava G, Kalin MF, Wolf SA. Regulation of insulin receptors in the human ovary: in vitro studies. J Clin Endocrinol Metab 67: 774–778, 1988.
Poretsky L, Bhargava G, Saketos M, Dunaif A. Regulation of human ovarian insulin receptors in vivo. Metabolism 39: 161–166, 1990.
Saltiel AR. Second messengers of insulin action. Diabetes Care 13: 244256, 1990.
Nestler JE, Jakubowicz DJ, De Vargas AF, Brik C, Quintero N, Medina F. Insulin stimulates testosterone biosynthesis by human thecal cells from women with polycystic ovarian syndrome by activating its own receptor and using inositolglycan mediators as the signal transduction system. J Clin Endocrinol Metab 83: 2001–2005, 1998.
Poretsky L, Seto-Young D, Shrestha A, Dhillon S, Mirjany M, Liu H-C, Yih MC, Rosenwaks Z. Phosphatidyl-inositol-3 kinase-independent insulin action pathway(s) in the human ovary. J Clin Endocrinol Metab 86: 3115–3119, 2001.
Poretsky L, Glover B, Laumas V, Kalin M, Dunaif A. The effects of experimental hyperinsulinemia on steroid secretion, ovarian [125I] insulin binding, and ovarian [1251] insulin-like growth factor I binding in the rat. Endocrinology 122: 581–585, 1988.
Samoto T, Maruo T, Matsuo H, Katayama K, Barnea ER Mochizuki M. Altered expression of insulin and insulin-like growth factor-I receptors in follicular and stromal compartments of polycystic ovarian ovaries. Endocr 40: 413–424, 1993.
Willis D, Mason H, Gilling-Smith C, Franks S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab 81: 302–309, 1996.
Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 335: 617–23, 1996.
Sahin Y, Ayata D, Kelestimur F. Lack of relationship between 17hydroxyprogesterone response to buserelin testing and hyperinsulinemia in polycystic ovary syndrome. Eur J Endocrinol 136: 410–415, 1997.
Fulghesu AM, Villa P, Pavone V, Guido M, Apa R, Caruso A, Lanzone A, Rossodivita A, Mancuso S. The impact of insulin secretion on the ovarian response to exogenous gonadotropins in polycystic ovarian syndrome. J Clin Endocrinol Metab 82: 644–648, 1997.
Stuart CA, Nagamani M. Acute augmentation of plasma androstenedione and dehydroepiandrosterone by euglycemic insulin infusion: evidence for a direct effect of insulin on ovarian steroidogenesis. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR eds. Polycystic Ovary Syndrome. Boston: Blackwell Scientific Publications; 279–288, 1992.
Stuart CA, Prince MJ, Peters EJ, Meyer WJ. Hyperinsulinemia and hyperandrogenemia: in vivo androgen response to insulin infusion. Obstet Gynecol 69: 921–925, 1987.
Poretsky L, Piper B. Insulin resistance, hypersecretion of LH, and a dual-defect hypothesis for the pathogenesis of polycystic ovary syndrome. Obstet Gynecol 84: 613–621, 1994.
Adashi EY, Hsueh AJW, Yen SSC. Insulin enhancement of luteinizing hormone and follicle-stimulating hormone release by cultured pituitary cells. Endocrinology 108: 1441–1449, 1981.
Soldani R, Cagnacci A, Yen SS. Insulin, insulin-like growth factor I (IGF I) and IGF-II enhance basal and gonadotropin-releasing hormone-stimulated luteinizing hormone release from rat anterior pituitary cells in vitro. Eur J Endocrinol 131: 641–645, 1994.
Nestler JE, Jakubowicz DJ. Lean women with polycystic ovary syndrome respond to insulin reduction with decreases in ovarian P450c17 alpha activity and serum androgens. J Clin Endocrinol Metab 82: 4075–9, 1997.
Dunaif A, Graf M. Insulin administration alters gonadal steroid metabolism independent of changes in gonadotropin secretion in insulin-resistant women with polycystic ovary syndrome. J Clin Invest 83: 23–29, 1989.
Plymate SR, Matej LA, Jones RE, Friedl KE. Inhibition of sex hormone-binding globulin production in the human hepatoma (HepG2) cell line by insulin and prolactin. J Clin Endocrinol Metab 67: 460–464, 1988.
Peiris AN, Stagner JL, Plymate SR, Vogel RL, Heck M, Samols E. Relationship of insulin secretory pulses to sex hormone-binding globulin production in normal men. J Clin Endocrinol Metab 76: 279–282, 1993.
Fendri S, Arlot S, Marcelli JM, Dubreuil A, Lalau JD. Relationship between insulin sensitivity and circulating sex hormone-binding globulin levels in hyperandrogenic obese women. Int J Obes Relat Metab Disord 18: 755–759, 1994.
Nestler JE, Powers LP, Matt DW, Steingold KA, Plymate SR, Rittmaster RS, Clore JN, Blackard WG. A direct effect of hyperinsulinemia on serum sex hormone-binding globulin levels in obese women with the polycystic ovary syndrome. J Clin Endocrinol Metab 72: 83–89, 1991.
Pao CI, Farmer PK, Begovic S, Villafuerte BC, Wu G, Robertson DG, Phillips LS. Regulation of insulin-like growth factor-I (IGF I) and IGFbinding protein I gene transcription by hormones and provision of amino acids in rat hepatocytes. Mol Endocrinol 7: 1561–1568, 1993.
Lee PD, Giudice LC, Conover CA, Powell DR. Insulin-like growth factor binding protein-1: recent findings and new directions. Proc Soc Exp Biol Med 216: 319–357, 1997.
Giudice LC. Insulin-like growth factors and ovarian follicular development. Endocr Rev 13: 641–669, 1992.
Nagami M, Stuart CA. Specific binding sites for insulin-like growth factor I in the ovarian stroma of women with polycystic ovarian disease and stromal hyperthecosis. Am J Obstet Gynecol 163: 1992–1997, 1990.
Duleba AJ, Spaczynski RZ, Olive DL, Behrman HR. Effects of insulin and insulin-like growth factors on proliferation of rat ovarian theca-interstitial cells. Biol Reprod 56: 891–897, 1997.
Duleba AJ, Spaczynski RZ, Olive DL. Insulin and insulin-like growth factor I stimulate the proliferation of human ovarian theca-interstitial cells. Fertil Steril 69: 335–340, 1998.
Watson H, Willis D, Mason H, Modgil G, Wright C, Franks S. The effects of ovarian steroids, epidermal growth factor (EGF), insulin (I), and insulin-like growth factor-1 (IGF-I), on ovarian stromal cell growth. Program of the 79th Annual Meeting of the Endocrine Society, Minneapolis, MN, (Abstract 389 ), 1997.
Bogovich K, Clemons J, Poretsky L. Insulin has a biphasic effects on the ability of human chorionic gonadotropin to induce ovarian cysts in the rat. Metabolism 48: 995–1002, 1999.
Damario M, Bogovich K, Liu HC, Rosenwaks Z, Poretsky L. Synergistic effects of IGF-I and human chorionic gonadotropin in the rat ovary. Metabolism 49: 314–320, 2000.
De C1ueTJ, Shah SC, Marchese M, Malone JI. Insulin resistance and hyperinsulinemia induce hyperandrogenism in a young type B insulin-resistant female. J Clin Endocrinol Metab 72: 1308–1311, 1991.
Dunaif A, Finegood DT. Beta-cell dysfunction independent of obesity and glucose intolerance in the polycystic ovary syndrome. J Clin Endocrinol Metab 81: 942–947, 1996.
Legro R, Kunselman A, Dodson W, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a perspective, controlled study in 254 affected women. J Clin Endocrinol Metab 84: 165–169, 1999.
Koivunen RM et al. Metabolic and steroidogenic alterations related to increased frequency of polycystic ovaries in women with a history of gestational diabetes. J Clin Endocrinol Metab 86: 2591–2599, 2001.
The Diabetes Prevention Program Research Group. The Diabetes Prevention Program: baseline characteristics of the randomized cohort. Diabetes Care 23 (11): 1619–1629, 2000.
Fujimoto W. Background and recruitment data for the U.S. Diabetes Prevention Program. Diabetes Care 23: B11 - B13, 2000.
Board JA, Rosenberg SM, Smeltzer JS. Spironolactone and estrogenprogestin therapy for hirsuitism. South Med J 80: 483–486, 1987.
Falsetti L. Gamera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome. Human Reproduction 16: 36–42, 2001.
Dewis P, Petsos P, Newman M, Anderson DC. The treatment of hirsuitism with a combination of desogestrel and ethinyl oestradiol. Clin Endocrinol 22: 29–36, 1985.
Bates GW, Whitworth NS. Effect of body weight reduction on plasma androgens in obese infertile women. Fertil Steril 38: 406–409, 1982.
Pasquali R, Antenucci D, Casimirri F, Venturoli S, Paradisi R, Fabbri R, et al. Clinical and hormonal characteristics of obese and amenorrheic women before and after weight loss. J Clin Endocrinol Metab 68: 173–9, 1989.
Clark AM, Thornley B, Tomlinson L, Galletley C, Norman RJ. Weight loss in obese infertile women results in improvement in reproductive outcome for all forms of fertility treatment. Hum Reprod 13: 1502–5, 1998.
Crave JC, Fimbel S, Lejeune H, Cugnardey N, DeChaud H, Pugeat M. Effects of diet and metformin administration on sex hormone-binding globuliln, androgens, and insulin in hirsute and obese women. J Clin Endocrinol Metab 80: 2057–2062, 1995.
Moghetti P. Castello R. Negri C. Tosi F. Perrone F. Caputo M. Zanolin E. Muggeo M. Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. J Clin Endocrinol Metab 85: 13946, 2000.
Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 338: 1876–1880, 1998.
Bloomgarden ZT, Futterwiet W, Poretsky L. The use of insulin-sensitizing agents in patients with polycystic ovary syndrome. Endocr Pract. 7: 279–286, 2001.
Velazquez E. Acosta A, Mendoza SG. Menstrual cyclicity after metformin therapy in polycystic ovary syndrome. Obstetrics and Gynecology 90: 392–395, 1997.
Jakubowicz DJ, Seppala M, Jakubowicz S, Rodriguez-Armas O, Rivas-Santiago A, Koistinen H, Koistinen R, Nestler JE. Insulin reduction with metformin increases luteal phase serum glycodelin and insulin-like growth factor-binding protein 1 concentrations and enhances uterine vascularity and blood flow in the polycystic ovary syndrome. J Clin Endocrinol Metab 86: 1126–1133, 2001.
Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 81: 3299–3306, 1996.
Azziz R, Ehrmann D, Legro RS, Whitcomb RW, Hanley R, Fereshetian AG, O’Keefe M, Ghazzi MN. Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: A multicenter, double blind, placebo-controlled trial. J Clin Endocrinol Metab 86: 1626–1632, 2001.
Nestler JE, Jakubowicz DJ, Reamer P, Gunn RD, Allan G. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 340: 1314–1320, 1999.
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2004 Springer Science+Business Media New York
About this chapter
Cite this chapter
Zweig, S.B., Tolentino, M.C., Poretsky, L. (2004). Polycystic Ovary Syndrome. In: Poretsky, L. (eds) Principles of Diabetes Mellitus. Springer, Boston, MA. https://doi.org/10.1007/978-1-4757-6260-0_38
Download citation
DOI: https://doi.org/10.1007/978-1-4757-6260-0_38
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4757-6262-4
Online ISBN: 978-1-4757-6260-0
eBook Packages: Springer Book Archive